By Chris Wood, Casey Research As an analyst who spends a great deal of time researching biotech and pharma companies, I'm well aware of the challenges facing the drug industry in the US today. From onerous regulation and an approval process that has made drug development prohibitively costly and...
By Chris Wood, Editor, Casey Research Here at Casey Research, we really don’t enjoy being a buzz-kill. It’s just that we think it’s more important for investors to be well informed about the reality in which we find ourselves today than it is to be happy-go-lucky all the time. The good...